Completed PHASE3 INTERVENTIONAL 2-arm NCT01823159

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (CERETI)

Sponsor: GlaxoSmithKline

Conditions Epilepsy

Updated 5 times since 2017 Last updated: Dec 1, 2014 Started: Apr 30, 2013 Primary completion: Dec 31, 2013 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01823159, this PHASE3 trial focuses on Epilepsy and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University Hospital of Mont-Godinne
Université Catholique de Louvain

Data source: University Hospital of Mont-Godinne

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yvoir, Belgium